Amgen names David Piacquad Senior Vice President, Business Development
12 March 2014 | By Amgen
Amgen announced the appointment of David Piacquad to the new position of senior vice president, Business Development...
List view / Grid view
News
Sanofi and UCB partner for breakthrough innovation in immune-mediated diseases
11 March 2014 | By Sanofi
Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules...
10,000 patients with atrial fibrillation now enrolled in innovative GLORIA™-AF Registry
11 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces the enrolment of the 10,000th patient with atrial fibrillation (AF) into GLORIA™-AF, one of the largest AF registry programmes currently running worldwide...
Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation
11 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer
10 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that GSK has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India (GlaxoSmithKline Pharmaceuticals Limited), from 50.7% to 75%...
Merck’s Consumer Health division breaks $1bn barrier through transition of Neurobion and Floratil brands from Merck Serono
10 March 2014 | By Merck
Move reinforces business strategy to reach a minimum of 3% total share per key market and at least 3 leading brands in investment markets...
Waters ACQUITY QDa Detector takes Pittcon Editors’ Award
10 March 2014 | By Waters
2014 Honor marks fourth time in last ten years Waters' has been recognized by Pittcon Media Corps...
Rigaku Raman Technologies unveils new Progeny Material ID Handheld Raman Analyzer; Redefines performance, ruggedness and ease-of-use
10 March 2014 | By Rigaku
Rigaku Raman Technologies announced its next generation handheld analyzer, the Rigaku Progenyä, designed from the ground up to deliver the industry’s most comprehensive and accurate materials identification, and improved ease of use, adaptability and reliability...
Teva Pharmaceuticals and Volunteers in Medicine partner to expand access to healthcare in the U.S.
10 March 2014 | By Teva
Teva Pharmaceuticals USA and Volunteers in Medicine announced their 2014 National Partnership to make healthcare services more readily available to the uninsured...
New Roche test helps specialists to identify syphilis in routine samples and donated blood
7 March 2014 | By Roche
Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease...
Novartis announces positive Phase III study for Jakavi® in patients with rare blood cancer polycythemia vera
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
Announcement regarding the project of H5N1 influenza vaccines
7 March 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced in August 2011 that the group company Kitasato Daiichi Sankyo Vaccine Company, Limited was selected for the Japanese Ministry of Health, Labour and Welfare's cell culture vaccine production facility capacity building grant...
Sanofi’s Board of Directors propose appointment of Patrick Kron as new independent Director
6 March 2014 | By Sanofi
At its meeting held on March 5, 2014, the Board of Directors of Sanofi proposed the appointment of Patrick Kron as a new independent Director...
Novartis announces Xolair® approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines
6 March 2014 | By Novartis
Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients...
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
6 March 2014 | By Boehringer Ingelheim
More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...
